Correspondence  by unknown
amine infusion before the decrease. By contrast, the observations of
Cladellas et al. concern patients who failed to achieve an adequate
heart rate response; it is not clear whether heart rate decrease
occurred in any patient. As we reported, only 1 of 14 patients with
paradoxical sinus deceleration was taking beta-blockers. We men-
tioned in our report that all our patients fasted for at least 3 h before
dobutamine stress echocardiography; mild hypovolemia may have
facilitated the occurrence of the vasodepressor response.
In our conclusions, we reported that paradoxical sinus deceleration
was most often seen in patients with coronary artery disease, but in
14% of our patients with heart rate decrease, there were no angio-
graphic, echocardiographic, electrocardiographic or clinical signs of
coronary artery disease. Sinus deceleration was often accompanied by
a decrease in blood pressure, nausea and chest pain. We believe that
sinus deceleration during dobutamine stress echocardiography is typ-
ically mediated by the Bezold-Jarisch reflex and is most commonly
seen in the presence of ischemia but may occur in its absence.
The echocardiographic signs of myocardial ischemia may be subtle
if heart rate is not increased and can be best appreciated by continuous
echocardiographic surveillance. Atropine is effective in increasing
heart rate in patients with paradoxical bradycardia and is recom-
mended in those with no manifestations of ischemia.
CHRISTINE H. ATTENHOFER JOST, MD
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F-18 FDG Uptake in Transplanted Heart
In their recent report, Rechavia et al. (1) concluded that a threefold
increase in the uptake of the glucose tracer analogue fluorine-18
2-deoxy-2-fluoroglucose (F-18 FDG) in transplanted hearts reflects a
preference for glucose as a substrate. The authors further concluded
that this preference for glucose may be due either to inefficient
utilization of glucose by the transplanted heart or to the influence of
circulating catecholamines.
This observation can be explained entirely by a change in the
relation between F-18 FDG and glucose. The latter is commonly
referred to as the “lumped constant” (LC) (2). This ratio between
tracer (F-18 FDG) and tracee (glucose) reflects the kinetic differences
between glucose and deoxyglucose transport and phosphorylation.
Most studies have used a fixed value of 0.67 to quantitate glucose
uptake from the F-18 FDG tracings (3–5), but we (6,7) and others (8)
have recently observed in the isolated working heart that the LC is
subject to significant variability, depending on the metabolic environ-
ment. Insulin and competing substrates to glucose cause a decrease in
the LC (6–8), whereas epinephrine and ischemia can cause an increase
in the LC (unpublished observations). An increase in the LC causes an
overestimation of glucose uptake, whereas a decrease in the LC results
in an underestimation of glucose uptake.
Thus, considering the results of Rechavia et al. (1) in light of the
experimental findings (6–8), the concept of an increased LC in the
transplanted hearts is in order. Such an increase would lead to the over-
estimation of glucose uptake. This effect may artificially introduce and
accentuate otherwise minor differences in glucose uptake. The possi-
bility of increased catecholamine sensitivity and the possible presence
of chronic “demand ischemia” in transplanted hearts would argue in
favor of this hypothesis.
A practical solution to this problem would be to determine the LC
individually for every study from the time-activity curves of F-18 FDG
accumulation (9). The results presented by Rechavia et al. (1) are
undoubtedly interesting, but we caution against drawing any conclu-
sions regarding the quantitation of glucose uptake or metabolism in
transplanted human heart.
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Reply
In their comment on the report by Rechavia et al. (1), Doenst and
Taegtmeyer make several important statements about the lumped
constant (LC) for fluorine-18 2-fluoro-2-deoxy-D-glucose (F-18 FDG)
and how changes in this variable would reflect on the quantitative
assessment of myocardial glucose utilization with this method. They
also surmize how the LC may differ between fasting conditions in
normal subjects and in transplant recipients.
We agree with the view that it is important to develop an
understanding of how the kinetics of F-18 FDG and glucose differ
under varying pathophysiologic conditions in humans, but the absence
of appropriate and unequivocal data means that predictions of how the
LC might change clinically are still clearly speculative.
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The results of various studies performed in isolated hearts support
the notion that the potential range of changes in the value of the LC
in humans may be substantial, although in the recent paper by Bøtker
et al. (2), a reanalysis of data previously presented by Krivokapich et al.
(3), shows a less than twofold variation in the LC for various
physiologic changes (with values ranging between 0.45 and 0.85). In the
same report (2), estimations of the LC are made for two subjects in the
fasting state by means of the kinetics of F-18 FDG (the K1:K1 ratio).
Although this approach looks very promising, there are no reliable
data presented for the magnitude and range of values for the LC in
fasting humans.
Regarding the possible differences in the LC between the normal
and the transplanted heart, Doenst and Taegtmeyer suggest the
likelihood of an increase in the LC under conditions of increased
epinephrine or ischemia (unpublished observations). In the report by
Rechavia et al. (1), the possibility is raised that F-18 FDG uptake (and
therefore glucose utilization) may be increased because of a state of
chronic “demand ischemia.” This state is proposed in the context of a
substrate modifier, and in view of the modest increase in baseline
workload of the hearts in these patients (53%—with a proportionate
41% increase in flow relative to that in normal control subjects), it is
unrealistic to equate the status of the transplanted heart with full-
blown acute myocardial ischemia.
In their letter, Doenst and Taegtmeyer suggest that they have
evidence (unpublished observations) for an increase in the value of the
LC with epinephrine; yet (as an illustration of the variability in the
findings on this subject) they have themselves published data (4)
suggesting a constant relation between the kinetic behavior of F-18
FDG and glucose during the administration of epinephrine (i.e., a
constant value for the LC). Of equal importance, no indication for
changes in the value of the LC were noted in the same studies during
conditions of acute increase in workload. The additional finding that
F-18 FDG uptake was not increased during the administration of
insulin in those studies, contrary to the result of extensive experi-
ment in humans and documented in Bøtka et al. (2), highlights the
problem of extrapolating results from experimental animal models
to humans.
Taken together, these findings do not support the notion that a
significant difference in the value of the LC exists for the transplanted
heart. It is therefore not unreasonable to interpret the finding of a
threefold increase in F-18 FDG uptake in the heart transplant
recipients (1) as an increase in the rate of glucose utilization. However,
we do agree that there is a need for a simple and quantitative in vivo
assessment of the LC, such as that proposed by Bøtker et al. (2).
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QT Dispersion as a Marker of Risk in
Patients Awaiting Heart Transplantation?
We read with interest the report by Pinsky et al. (1) in a recent issue
of the Journal on a possible new application of QT dispersion from the
12-lead surface electrocardiogram (ECG). The question of whether
QT dispersion is a useful risk marker in patients with congestive heart
failure is still under dispute (1–7). Pinsky et al. (1) reported that QT
dispersion predicts death in patients awaiting list heart transplantation.
In their conclusion, the authors claim that the index “may help to
establish priority on a heart transplant waiting list.” Obviously, such
priority decisions may mean “life or death” in a given patient. The
validity and objectivity of a risk stratification test in this setting are
therefore of utmost importance.
Concerning the use of QT dispersion as a marker of arrhythmic
events or death in patients with congestive heart failure, the contrast-
ing results of available studies (1,4–7) indicate that the role and
methodology of QT dispersion is far from settled and remains sensitive
to methodologic discrepancies. We and others (2,8) have devoted
research efforts to the methodology of QT dispersion that have led to
entirely negative results for patients with congestive heart failure
(5–7). The report by Pinsky et al. (1) raises a number of important
methodologic questions.
1. QT dispersion cutoffs were determined post hoc, identifying a
high risk patient group of six patients with QT dispersion .140 ms.
Instead of calculating an odds ratio for such a small group, receiver
operator characteristic curves could have yielded more valid statistical
information. The average QT dispersion for both the event and
nonevent groups was found to be significantly higher than that in
published reports (4,6) and our own data (5,7). In our view, such
extreme QT dispersion values must raise the suspicion of measurement
errors.
2. An exact description of U wave identification was given; how-
ever, the incidence of U waves, which may have contributed to an
increased QT dispersion, is not mentioned in the results section.
3. The reader is unable to discern whether measurements were
taken by hand, by digitizing pad or with or without magnifying glasses.
Notably, only six measurable ECG leads were required. Apparently, a
4 3 3 lead ECG display was used, which does not give simultaneous
information for all 12 leads. This method is susceptible to errors
caused by transient changes in the RR interval and associated QT
intervals and may have increased the overall QT dispersion.
4. Patients with atrial fibrillation (n 5 13) were included in the
analysis. Again, changing RR and QT intervals between different beats
prohibits accurate determination of QT dispersion.
5. No information on the reproducibility of the measurements was
provided. Accurate measurement of QT intervals and QT dispersion,
which is prone to subjective operator errors, requires stringent controls
by comparing data from at least two independent blinded operators.
The discussion of the report, in our view, does not adequately
consider methodologic considerations or limitations. In conclusion, we
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